Summary
Virtus Biotech ETF is an ETF - a fund traded on an exchange like a stock - run by Virtus. Positions inside: 67. The ten largest make up 28% of the fund.
- Yearly costs
- 0.34%
- Fund size
- $131.6M
- Positions
- 67
- Dividends
- Reinvested
- Running since
- 2014
What speaks for it
- Costs of 0.34% a year are below the middle of comparable funds (0.44%).
- Average yearly growth over the last ten years: 12%.
- It has been running since 2014.
What to watch
- 100% of the fund is in one sector (Healthcare).
- 95% of the fund is in one country (United States).
- In the last five years its price once dropped by 44% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -2.3%
- 3 months
- +1.9%
- This year
- +28%
- 1 year
- +38%
- 3 years
- +119%
- 5 years
- +99%
- 10 years
- +203%
- Avg. market cap
- $28.6B
- P/E
- -
- Forward P/E
- -
- P/S
- 0.6x
- P/B
- 0.1x
- P/FCF
- 0.7x
- EV/EBITDA
- 15.6x
- Dividend yield
- 0.09%
- ROIC
- -11.1%
- ROE
- -14.5%
- Gross margin
- 63.6%
- Operating margin
- -445.5%
- Net margin
- -140.1%
- Payout ratio
- -
- Net debt/EBITDA
- 0.6x
- Beta
- 0.71
Weighted average of the 50 largest companies, which make up 86% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Widely spread- 1 MRModerna MRNA 6.5%
- 2 VSVerastem, Inc. VSTM 3.1%
- 3 OMOmeros Corporation OMER 2.6%
- 4 XEXeris Biopharma Holdings, Inc. XERS 2.6%
- 5 IOIovance Biotherapeutics, Inc. IOVA 2.5%
- 6 HAHalozyme Therapeutics HALO 2.4%
- 7 KNKiniksa Pharmaceuticals International, plc KNSA 2.3%
- 8 ADADMA Biologics ADMA 2.2%
- 9 RERegeneron Pharmaceuticals REGN 2.0%
- 10 BeOne Medicines Ltd 2.0%
Positions in the fund: 67. The ten largest make up 28% of it.
Composition as of Nov 7, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 95%
- China 1.7%
- United Kingdom 1.6%
- Switzerland 1.4%
By company size
- Mega cap 3.6%
- Large cap 30%
- Mid cap 41%
- Small cap 25%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (95%). Largest size group: Mid cap (41%).
What does it cost me?
Cheap- A year from $10,000
- $34.00
- Over 20 years
- $1,666
From every $10,000 invested the fund takes $34.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $1,666.
How has it done?
Growing over the long run- A year on average, 10 years
- +12%
- Deepest drop
- -44%
- Yearly volatility
- 27%
Average yearly growth over the last ten years: 12%. Deepest drop in these years: 44% below the earlier high.
Does it pay dividends?
No, it reinvestsThe fund pays nothing out. What its holdings earn stays inside and shows in the price.
Is it easy to buy and sell?
Yes- Traded a day
- $1.20M
- Shares a day
- 12K
On an average day about $1.20M of the fund changes hands.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 50 out of 100
Weight by Bulios Fair Price
- Undervalued 29%
- Fairly valued 12%
- Overvalued 60%
By Fair Price, 60% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 86% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $26.6M | +28% | Reinvests | 48% |
XB XBI SPDR S&P Biotech ETF | United States | 0.35% | $7.96B | +40% | Pays out | 48% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $84.9M | +36% | Pays out | 38% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $954.9M | +43% | Reinvests | 38% |
20 203780.KS MiraeAsset TIGER NASDAQ BIO ETF | South Korea | 0.30% | $77.5M | +24% | Reinvests | 37% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $11.1B | +35% | Pays out | 37% |
